Johnson & Johnson Reports Q1 2025 Financial Results with Strong Sales Growth and Dividend Increase

Details

The company's earnings per share (EPS) increased to $4.54, reflecting operational growth of 4.2% and adjusted operational growth of 3.3%. Additionally, the Board of Directors declared a 4.8% increase in the quarterly dividend, marking the 63rd consecutive year of dividend increases. The new dividend rate is $1.30 per share, payable on June 10, 2025 to shareholders of record as of May 27, 2025. The company also highlighted significant progress in its product pipeline, including approvals and data releases for various treatments and technologies.

Items reported

Exhibits (3)

About Johnson & Johnson

Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.